

WRHA HAZARDOUS MEDICATIONS LIST¹

CYTOTOXIC HAZARDOUS MEDICATIONS			
ado-trastuzumab emtansine	dabrafenib	ibrutinib	raltitrexed
afatinib	dacarbazine	IDArubicin	regorafenib
altretamine	DACTINomycin	ifosfamide	romidepsin
amsacrine	dasatinib	imatinib ²	ruxolitinib
arsenic	DAUNOrubicin	irinotecan	
axitinib	deferiprone		SORAFenib
azaCITIDine	dexrazoxane	lapatinib	streptozocin
azaTHIOprine ²	DOCEtaxel	lenalidomide	SUNItinib
	DOXOrubicin	lomustine	
bendamustine			temozolomide
bleomycin	epirubicin	mechlorethamine	temsirolimus
bortezomib	eribulin	melphalan	teniposide
bosutinib	erlotinib ²	mercaptopurine	thalidomide
brentuximab vedotin	estramustine	methotrexate ²	thioguanine
busulfan ²	etoposide	mitoMYcin	thiotepa
		mitoXANtrone	topotecan
			trametinib
cabazitaxel	floxuridine		
capecitabine ²	flucytosine	nelarabine	valGANciclovir ²
CARBOplatin	fludarabine	nilotinib	valrubicin
carmustine	fluorouracil		vandetanib
chlorambucil		oxaliplatin	vemurafenib
CISplatin	ganciclovir		vinBLASline
cladribine	gefitinib ²	PACLitaxel	vinCRISline
clofarabine	gemcitabine	pazopanib	vinorelbine
crizotinib	gemtuzumab ozogamicin	PEMEtrexed	vorinostat
cyclophosphamide		pentostatin	
cytarabine	hydroxyurea	phenoxybenzamine	
		procarbazine ²	

SEE PAGE 2 FOR NON-CYTOTOXIC HAZARDOUS MEDICATIONS

- The following groups of products are not listed on the WRHA Cytotoxic and Non-Cytotoxic Hazardous Medications List but require handling precautions.
 - Salts, pegylated and liposomal medications; only the parent compound is listed. Handle all derivatives of a hazardous medication the same as the parent compound.
 - Combination products containing one or more hazardous medications shall be handled as hazardous medications (e.g. Arthrotec[®] which contains misoprostol and diclofenac).
 - Radioactive pharmaceuticals; nuclear medicine has policies and procedure for safe handling of radioactive pharmaceuticals. These products are generally not handled by pharmacy.
 - Chemicals / raw powders; see the Material Safety Data Sheet (MSDS) for safe handling precautions.
- "Dissolve and dose" may be considered as a method of oral administration when a liquid preparation is required.

ACKNOWLEDGEMENT: This list is adapted from the *National Institute for Occupational Safety and Health (NIOSH) List of Antineoplastic and other Hazardous Drugs in Healthcare Settings, 2014* for use in WRHA facilities and CancerCare Manitoba.

The list is revised as new medications or information become available.

Revised and Effective February 2016

Prepared by WRHA Regional Pharmacy Program, St Boniface Hospital Pharmacy Department and Pharmacy Department, CancerCare Manitoba

For the most recent version of this list go to: http://home.wrha.mb.ca/prog/pharmacy/medications_safehandling.php

WRHA HAZARDOUS MEDICATIONS LIST¹

NON - CYTOTOXIC HAZARDOUS MEDICATIONS		
abiraterone	finasteride ²	nafarelin
acitretin	fingolimod	nilutamide ²
alitretinoin	fluoxymesterone ²	
ambrisentan	flutamide ²	oxandrolone ²
anastrozole ²	foscarnet	
	fulvestrant	pentamidine (aerosol only)
bacillus calmette guerin ³ (bladder instillation only)		podofilox
bexarotene	ganirelix	podophyllum resin
bicalutamide ²	goserelin	
bosentan		raloxifene ²
buserelin	iloprost	ribavirin
	ISOtretinoin	
cetorelix	leflunomide ²	sirolimus
choriogonadotropin alfa	letrozole ²	tacrolimus
cidofovir	leuprolide	tamoxifen ²
clomiPHENE		testosterone
colchicine ²	megestrol ²	tretinoin
cycloSPORINE	methacholine	trifluridine
cyproterone	methylTESTOSTERone	triptorelin
	mifepristone	
degarelix	misoprostol ²	
dinoprostone ²	mitotane	
dutasteride	mycophenolate mofetil	
	mycophenolic acid	
everolimus		
exemestane ²		

SEE PAGE 1 FOR CYTOTOXIC HAZARDOUS MEDICATIONS

- The following groups of products are not listed on the WRHA Cytotoxic and Non-Cytotoxic Hazardous Medications List but require handling precautions.
 - Salts, pegylated and liposomal medications; only the parent compound is listed. Handle all derivatives of a hazardous medication the same as the parent compound.
 - Combination products containing one or more hazardous medications shall be handled as hazardous medications (e.g. Arthrotec[®] which contains misoprostol and diclofenac).
 - Radioactive pharmaceuticals; nuclear medicine has policies and procedure for safe handling of radioactive pharmaceuticals. These products are generally not handled by pharmacy.
 - Chemicals / raw powders; see the Material Safety Data Sheet (MSDS) for safe handling precautions.
- "Dissolve and dose" may be considered as a method of oral administration when a liquid preparation is required.
- Bacillus Calmette Guerin (BCG), when used for bladder instillation, shall be prepared following the instructions provided with the closed system reconstitution kit and in the *Bladder Instillation of Bacillus Calmette-Guerin (BCG) & BCG/Interferon for the Treatment of Bladder Cancer Directive*. See: <http://home.wrha.mb.ca/prog/surgery/files/BCGOPERATIVEDIRECTIVE.pdf>

ACKNOWLEDGEMENT: This list is adapted from the *National Institute for Occupational Safety and Health (NIOSH) List of Antineoplastic and other Hazardous Drugs in Healthcare Settings*, 2014 for use in WRHA facilities and CancerCare Manitoba.

The list is revised as new medications or information become available.

Revised and Effective February 2016

Prepared by WRHA Regional Pharmacy Program, St Boniface Hospital Pharmacy Department and Pharmacy Department, CancerCare Manitoba

For the most recent version of this list go to: http://home.wrha.mb.ca/prog/pharmacy/medications_safehandling.php